Autopsy report · NCT05263492

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

“Closed early due to low enrollment rates”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 7 months before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Virginia Commonwealth University

Sponsor type

University, hospital or other

Conditions

Endometrial Cancer; Mismatch Repair-Proficient; Recurrent Endometrial Cancer

Interventions

Lenvatinib; Pembrolizumab

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
  “Closed due to slow enrollment” (80% match in meaning)
• MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction
  “low enrollment rate” (75% match in meaning)
• Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1
  “Low rate of enrollment” (75% match in meaning)
• A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema
  “Halted prematurely due to low enrollment” (74% match in meaning)
• Reconstruction Flaps for Nasal Surgical Wounds RCT
  “Study closed before enrollment could begin.” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.